References and Notes
<A NAME="RU31905ST-1A">1a</A>
Luzzio FA.
Piatt Zachert D.
Tetrahedron Lett.
1998,
39:
2285
<A NAME="RU31905ST-1B">1b</A>
Campbell JB.
Dedinas RF.
Trumbower-Walsh SA.
J. Org. Chem.
1996,
61:
6205
<A NAME="RU31905ST-1C">1c</A>
Decroix B.
Pigeon P.
. Tetrahedron Lett.
1996,
37:
7707
<A NAME="RU31905ST-1D">1d</A>
Decroix B.
Pigeon P.
Othman M.
Tetrahedron
1997,
53:
2495
<A NAME="RU31905ST-1E">1e</A>
Allin SM.
Northfield CJ.
Page MI.
Slawin AMZ.
Tetrahedron Lett.
1997,
38:
3627
<A NAME="RU31905ST-1F">1f</A>
Kundu NG.
Khan MW.
Tetrahedron Lett.
1997,
38:
6937
<A NAME="RU31905ST-1G">1g</A>
Kitching MS.
Clegg W.
Elsewood MRJ.
Griffin RJ.
Golding BT.
Synlett
1999,
997
<A NAME="RU31905ST-2A">2a</A>
Nannin G.
Griraldi PN.
Molgora G.
Biasoli G.
Spinelli F.
Logemann L.
Dradi E.
Zanni G.
Buttinoni A.
Tommasini R.
Arzneim. Forsch.
1973,
23:
1090
<A NAME="RU31905ST-2B">2b</A>
Hisamitsu Pharmaceutical Co., Inc. Japan Kokai Tokyo Koho 149257, 1980; Chem. Abstr. 1981, 94, 174879; address: P. J. Kocienski, School of Chemistry, Univerity of Leeds, Leeds
LS2 9JT, UK.
<A NAME="RU31905ST-3">3</A>
Schmahl H.-J.
Denker L.
Plum C.
Chahoud I.
Nau H.
Arch. Toxicol.
1996,
11:
749
<A NAME="RU31905ST-4">4</A>
Plowman J.
Paull KD.
Atassi G.
Harrison S.
Dykes D.
Kabbe N.
Narayan VL.
Yoder O.
Invest. New Drugs
1988,
6:
147
<A NAME="RU31905ST-5A">5a</A>
Ganesan A.
Wang H.
Tetrahedron Lett.
1998,
39:
9097
<A NAME="RU31905ST-5B">5b</A>
Anzani M.
Capelli A.
Vomero S.
Heterocycles
1994,
38:
103
<A NAME="RU31905ST-6">6</A>
Horii Z.
Iwata C.
Tamura Y.
J. Org. Chem.
1961,
26:
2273
<A NAME="RU31905ST-7">7</A>
Orito K.
Horibata A.
Nakamura T.
Ushito H.
Nagasaki H.
Yuguchi M.
Yamashita S.
Tokuda M.
J. Am. Chem. Soc.
2004,
126:
14342
<A NAME="RU31905ST-8">8</A>
Hoarau C.
Couture A.
Deniau E.
Grandclaudon P.
Synthesis
2000,
655
<A NAME="RU31905ST-9A">9a</A>
Späth E.
Lintner J.
Ber. Dtsch. Chem. Ges. B
1936,
69:
2727
<A NAME="RU31905ST-9B">9b</A>
Barrios I.
Camps P.
Comes-Franchini M.
Muñoz-Torrero D.
Ricci A.
Sánchez L.
Tetrahedron
2003,
59:
1971
<A NAME="RU31905ST-10">10</A> See for mechanical study:
Decker M.
Nguyen TTH.
Lehmann J.
Tetrahedron
2004,
60:
4567
<A NAME="RU31905ST-11">11</A>
Lesimple P.
Bigg DCH.
Synthesis
1991,
306
<A NAME="RU31905ST-12">12</A>
See ref. 6 for preparation of 6i.
<A NAME="RU31905ST-13">13</A>
Kornblum N.
Smiley RA.
Blackwood RK.
Iffland DC.
J. Am. Chem. Soc.
1955,
77:
6269
<A NAME="RU31905ST-14">14</A>
When 1 equiv of Grignard reagent was employed, O-protected compound 8 was obtained predominantly in entry 5.
<A NAME="RU31905ST-15">15</A>
Typical Experimental Procedure.
To a three-necked 50-mL round-bottomed flask equipped with dropping funnel were charged
DMI (15 mL) and o-hydroxymethylbenzamide 6a (1.35 g, 5.00 mmol). The resulting solution was cooled to 0 °C, and then 1.98 M of
i-PrMgCl-THF (5.63 mL, 11.15 mol, 2.23 equiv to 6a) was added dropwise. The resulting solution was warmed to ambient temperature and
stirred for 0.5 h. The solution was cooled to 0 °C, and then ClP(O)(NMe2)2 (0.94 mL, 6.50 mmol, 1.3 equiv to 6a) was added dropwise. The mixture was warmed to ambient temperature, and stirred for
14 h. The resulting solution was quenched by 2 N aq HCl (10 mL). The mixture was extracted
with i-PrOAc (3 × 10 mL), and the combined i-PrOAc extracts were washed with H2O (2 × 10 mL) and dried over anhyd Na2SO4. Removal of the solvent and subsequent silica gel chromatography (heptane and EtOAc)
afforded the corresponding lactam 1a in a pure form.
<A NAME="RU31905ST-16">16</A>
Spectroscopic Data for New Compounds.
Compound 6c: IR (neat): 1673, 1608, 1510, 1451, 1411, 1356, 1308, 1274, 1242, 1175, 1033, 1007,
837, 813, 768, 673 cm-1. 1H NMR (300 MHz, CDCl3): δ = 3.79 (s, 3 H), 4.22 (s, 2 H), 4.72 (s, 2 H), 6.86 (d, J = 8.5 Hz, 2 H), 7.24 (d, J = 8.5 Hz, 2 H), 7.53 (s, 1 H), 7.60 (d, J = 8.1 Hz, 1 H), 7.74 (d, J = 8.1 Hz, 1 H). 13C NMR (CDCl3): δ = 45.82, 48.77, 55.27, 114.18, 125.21, 125.93, 126.12, 128.75, 129.50, 131.47,
131.72, 142.97, 159.21, 167.38.
Compound 6f: IR (neat): 1658, 1460, 1409, 1367, 1303, 1234, 1057, 764, 737, 686 cm-1. 1H NMR (300 MHz, CDCl3): δ = 4.86 (s, 2 H), 7.18-7.21 (m, 1 H), 7.41-7.46 (m, 2 H), 7.48-7.53 (m, 2 H),
7.58-7.60 (m, 1 H), 7.86-7.89 (m, 2 H), 7.92-7.94 (m, 1 H). 13C NMR (CDCl3): δ = 50.71, 119.46, 122.59, 124.15, 124.46, 128.37, 129.14, 132.05, 133.24, 139.50,
140.09, 167.49.
Compound 6g: IR (neat): 2227, 1677, 1610, 1447, 1409, 1230, 1060, 877, 839, 770, 677 cm-1. 1H NMR (300 MHz, CDCl3): δ = 1.32 (d, J = 6.8 Hz, 6 H), 4.41 (s, 2 H), 4.69 (sept, J = 6.8 Hz, 1 H), 7.76 (d, J = 8.2 Hz, 1 H), 7.77 (s, 1 H), 7.94 (d, J = 8.2 Hz, 1 H). 13C NMR (CDCl3): δ = 20.75, 43.12, 44.90, 114.56, 118.31, 124.45, 126.75, 132.09, 137.32, 141.51,
165.88.